Communiqués Terumo Corporation

Actions

4543

JP3546800008

Equipement, fournitures et distribution médicale

Marché Fermé - Japan Exchange 08:30:00 20/08/2026			Varia. 5j.	Varia. 1 janv.
2 576,50 ^JPY	+4,23%		-1,68%	+13,50%

19/08	Résultats d'entreprises au Japon : Pan Pacific International et Terumo en repli	MT
12/08	Transcript : Terumo Corporation, Q1 2027 Earnings Call, Aug 07, 2026

Communiqués

01/07	Terumo : Announces Voluntary Recall of Specific Models of the Relay™Pro Thoracic Stent-Graft System in Global Markets	PU
13/06	Terumo : IR Day 2026 (with note)	PU
18/05	Terumo : Q&A Session at the Financial Results for the Fiscal Year Ended March 31, 2026	PU
18/05	Terumo : Financial Results for the Fiscal Year Ended March 31, 2026 (FY2025)(with note)	PU
15/05	Terumo : GS26 Final Year and Beyond & Terumo Neuro Growth Roadmap	PU
15/05	Terumo : Financial Results for the Fiscal Year Ended March 31, 2026 (FY2025)	PU
15/05	Terumo : IFRS Financial Results for the Fiscal Year Ended March 31, 2026	PU
15/05	Terumo : Announces Candidates for Directors	PU
14/05	OrganOx Announces Appointment of Naoya Iwata as CEO & President	AQ
30/04	Terumo : Issued its First U.S. Dollar-Denominated Senior Unsecured Notes	PU
15/04	Terumo Corporation Joins the Healthcare Plastics Recycling Council	AQ
19/02	Q-Sera announces the first launch of blood collection tubes using its patented Rapclot technology in Japan, opening opportunities for additional global partnerships	AQ
16/02	Terumo : Q&A Session at the Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026	PU
16/02	Terumo : Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026 (FY2025)(with note)	PU
13/02	Terumo : Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026 (FY2025)	PU
13/02	Terumo : IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026	PU
16/01	Terumo : J.P. Morgan Healthcare Conference 2026	PU
14/01	PRESSWIRE 2023: Diabeloop and Sequel Med Tech Enter Partnership to Integrate FDA-Cleared DBLG2 into the twiistâ„¢ Automated Insulin Delivery System	AQ
13/01	Terumo : 44th J.P.Morgan Healthcare Conference	PU
13/11	Terumo : Q&A Session at the Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2026	PU
13/11	Terumo : Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2026 (FY2025)(with note)	PU
12/11	Terumo : Notice Concerning Revisions to Full-Year Financial Guidance for Fiscal Year Ending March 31, 2026 (FY2025)	PU
12/11	Terumo : IFRS Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2026	PU
12/11	TIS Growth Roadmap: Advancing Terumo’s Core Business through the Launch of DSS	PU
12/11	Terumo : Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2026 (FY2025)	PU